Naturally occurring T cell mutations enhance engineered T cell therapies. Researchers identified that mutations found in T cell cancers can improve T cell therapies by enhancing signaling, cytokine production, and in vivo persistence. A gene fusion, CARD11–PIK3R3, found in a CD4+ cutaneous T cell lymphoma, was shown to enhance therapeutic T cell function and efficacy. This fusion significantly increases signaling pathways such as NF-κB and AP-1, and improves anti-tumor activity, reduces T cell dose requirements, and relieves the need for harsh lymphodepletion. The study demonstrated that CARD11–PIK3R3-expressing cells remained safe and did not show malignant transformation even after 418 days. The findings suggest that leveraging naturally occurring mutations could improve a wide range of T cell therapies. The study also showed that CARD11–PIK3R3 enhances CAR T cell function, improves tumor control, and increases survival in various models. The results indicate that CARD11–PIK3R3 enhances therapeutic efficacy while maintaining safety, even at high T cell doses. The study also highlights the importance of understanding the mechanisms of CARD11–PIK3R3 signaling in different T cell types and its potential for future therapeutic applications. The research provides insights into the role of T cell mutations in enhancing therapeutic T cell function and offers a promising approach for improving T cell therapies.Naturally occurring T cell mutations enhance engineered T cell therapies. Researchers identified that mutations found in T cell cancers can improve T cell therapies by enhancing signaling, cytokine production, and in vivo persistence. A gene fusion, CARD11–PIK3R3, found in a CD4+ cutaneous T cell lymphoma, was shown to enhance therapeutic T cell function and efficacy. This fusion significantly increases signaling pathways such as NF-κB and AP-1, and improves anti-tumor activity, reduces T cell dose requirements, and relieves the need for harsh lymphodepletion. The study demonstrated that CARD11–PIK3R3-expressing cells remained safe and did not show malignant transformation even after 418 days. The findings suggest that leveraging naturally occurring mutations could improve a wide range of T cell therapies. The study also showed that CARD11–PIK3R3 enhances CAR T cell function, improves tumor control, and increases survival in various models. The results indicate that CARD11–PIK3R3 enhances therapeutic efficacy while maintaining safety, even at high T cell doses. The study also highlights the importance of understanding the mechanisms of CARD11–PIK3R3 signaling in different T cell types and its potential for future therapeutic applications. The research provides insights into the role of T cell mutations in enhancing therapeutic T cell function and offers a promising approach for improving T cell therapies.